参考文章(123)
D G Harrison, D W Ferguson, S M Collins, D J Skorton, E E Ericksen, J M Kioschos, M L Marcus, C W White, Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. Circulation. ,vol. 69, pp. 991- 999 ,(1984) , 10.1161/01.CIR.69.5.991
Eugene Braunwald, Enhancing thrombolytic efficacy by means of “front-loaded” administration of tissue plasminogen activator Journal of the American College of Cardiology. ,vol. 14, pp. 1570- 1571 ,(1989) , 10.1016/0735-1097(89)90400-2
Prakash C. Deedwania, Enrique V. Carbajal, John R. Nelson, Howard Hait, Anti-Ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent Ischemia Journal of the American College of Cardiology. ,vol. 17, pp. 957- 962 ,(1991) , 10.1016/0735-1097(91)90880-I
Joe K. Bissett, William L. Ngo, Richard P. Wyeth, John P. Matts, Angiographic progression to total coronary occlusion in hyperlipidemic patients after acute myocardial infarction. American Journal of Cardiology. ,vol. 66, pp. 1293- 1297 ,(1990) , 10.1016/0002-9149(90)91156-Z
Burton E. Sobel, Jack Hirsh, Principles and practice of coronary thrombolysis and conjunctive treatment The American Journal of Cardiology. ,vol. 68, pp. 382- 388 ,(1991) , 10.1016/0002-9149(91)90836-A
G Melandri, A Branzi, F Semprini, V Cervi, N Galie, B Magnani, Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Heart. ,vol. 64, pp. 118- 120 ,(1990) , 10.1136/HRT.64.2.118
C L Grines, S E Nissen, D C Booth, J C Gurley, N Chelliah, R Wolf, J Blankenship, M C Branco, K Bennett, A N DeMaria, A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group. Circulation. ,vol. 84, pp. 540- 549 ,(1991) , 10.1161/01.CIR.84.2.540
P Golino, J H Ashton, L M Buja, M Rosolowsky, A L Taylor, J McNatt, W B Campbell, J T Willerson, Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators. Circulation. ,vol. 79, pp. 154- 166 ,(1989) , 10.1161/01.CIR.79.1.154